Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Anthony George Letai, M.D., Ph.D.

Title
Institution
Department
Address
Phone
Fax

Mentoring
Pharmacalogic Modulation of Tumor Associated Macrophages
Summer, 06/23/14 - 08/15/14
Apoptotic Priming, Chemosensitivity, and Proliferation in the Context of Stepwise Malignant Transformation
Summer, 06/20/11 - 08/12/11

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P01CA206978 (WU, CATHERINE JU-YING) Sep 1, 2016 - Aug 31, 2021
    NIH/NCI
    Comprehensive dissection of the CLL genome and phenome to improve patient outcomes
    Role: Co-Principal Investigator
  2. R01CA205967 (LETAI, ANTHONY G) Apr 1, 2016 - Mar 31, 2021
    NIH/NCI
    (PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
    Role: Principal Investigator
  3. R21CA188858 (LETAI, ANTHONY G) Aug 1, 2014 - Jul 31, 2016
    NIH/NCI
    Investigation of therapeutic modulators of apoptotic priming in pancreatic cancer
    Role: Principal Investigator
  4. P01CA139980 (MITCHISON, TIMOTHY J) Jun 1, 2010 - May 31, 2015
    NIH/NCI
    Mechanistic Pharmacology of Anti-Mitotics and Apoptosis Regulation
    Role: Co-Principal Investigator
  5. R01CA129974 (LETAI, ANTHONY G) Sep 26, 2007 - Jun 30, 2017
    NIH/NCI
    Probing mitochondria and personalizing leukemia therapy with BH3 profiling
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Slabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, Fulciniti M, Udeshi ND, Kuhn E, Letai A, Munshi NC, Carr SA, Ebert BL. Patterns of substrate affinity, competition and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019 May 01. PMID: 31043423.
    Citations:    
  2. Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019 Mar; 20(3):175-193. PMID: 30655609.
    Citations:    Fields:    
  3. Hong AL, Guerriero JL, Doshi MB, Kynnap BD, Kim WJ, Schinzel AC, Modiste R, Schlauch AJ, Adam RM, Kwiatkowski DJ, Beroukhim R, Letai A, Rosenberg JE, Hahn WC. MCL1 and DEDD Promote Urothelial Carcinoma Progression. Mol Cancer Res. 2019 Jun; 17(6):1294-1304. PMID: 30777879.
    Citations:    
  4. Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller AG, Cidado J, Letai A, Weinstock DM. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019 Feb 07; 133(6):566-575. PMID: 30498064.
    Citations:    
  5. Ariës IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pfirrmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson KE, Neuberg DS, Devidas M, Loh ML, Hunger SP, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, Wood BL, Silverman LB, Sallan SE, Van Vlierberghe P, Orkin SH, Knoechel B, Letai AG, Gutierrez A. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018 Dec 03; 215(12):3094-3114. PMID: 30404791.
    Citations:    Fields:    
  6. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 Jan 03; 133(1):7-17. PMID: 30361262.
    Citations:    Fields:    
  7. Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, Stachura J, Letai A, Lawton LN, Chapuy B, Shipp MA. Targeted inhibition of PI3Ka/d is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019 Jan 03; 133(1):70-80. PMID: 30322870.
    Citations:    Fields:    
  8. Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19). PMID: 30282833.
    Citations:    Fields:    
  9. Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood. 2018 09 06; 132(10):1007-1012. PMID: 30037885.
    Citations:    
  10. Kale J, Kutuk O, Brito GC, Andrews TS, Leber B, Letai A, Andrews DW. Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep. 2018 09; 19(9). PMID: 29987135.
    Citations:    Fields:    
  11. Kahn JD, Miller PG, Silver AJ, Sellar RS, Bhatt S, Gibson C, McConkey M, Adams D, Mar B, Mertins P, Fereshetian S, Krug K, Zhu H, Letai A, Carr SA, Doench J, Jaiswal S, Ebert BL. PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood. 2018 09 13; 132(11):1095-1105. PMID: 29954749.
    Citations:    Fields:    
  12. Taylor Ripley R, Surman DR, Diggs LP, Trepel JB, Lee MJ, Ryan J, Davis JL, Steinberg SM, Hernandez JM, Hoang C, Kenney CM, Bond CD, Kunst TF, Letai A, Schrump DS. Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy. BMC Gastroenterol. 2018 Jun 22; 18(1):94. PMID: 29933761.
    Citations:    Fields:    Translation:Humans
  13. Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA. Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 Jun 13; 10(445). PMID: 29899021.
    Citations:    Fields:    
  14. Letai A. Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia. J Clin Oncol. 2018 Jul 01; 36(19):1991-1993. PMID: 29787358.
    Citations:    Fields:    
  15. Gutierrez-Martinez P, Hogdal L, Nagai M, Kruta M, Singh R, Sarosiek K, Nussenzweig A, Beerman I, Letai A, Rossi DJ. Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nat Cell Biol. 2018 04; 20(4):413-421. PMID: 29531308.
    Citations:    
  16. Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan V, Bhola P, O'Donnell C, Spitzer B, Stutzke C, Lavallée VP, Hébert J, Krivtsov AV, Melnick A, Paietta EM, Tallman MS, Letai A, Sauvageau G, Pouliot G, Levine R, Marto JA, Armstrong SA, Kentsis A. MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov. 2018 04; 8(4):478-497. PMID: 29431698.
    Citations: 2     Fields:    
  17. Rezaei Araghi R, Bird GH, Ryan JA, Jenson JM, Godes M, Pritz JR, Grant RA, Letai A, Walensky LD, Keating AE. Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells. Proc Natl Acad Sci U S A. 2018 01 30; 115(5):E886-E895. PMID: 29339518.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  18. DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 02; 19(2):216-228. PMID: 29339097.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  19. Terai H, Kitajima S, Potter DS, Matsui Y, Quiceno LG, Chen T, Kim TJ, Rusan M, Thai TC, Piccioni F, Donovan KA, Kwiatkowski N, Hinohara K, Wei G, Gray NS, Fischer ES, Wong KK, Shimamura T, Letai A, Hammerman PS, Barbie DA. ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2018 02 15; 78(4):1044-1057. PMID: 29259014.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  20. Lagares D, Santos A, Grasberger PE, Liu F, Probst CK, Rahimi RA, Sakai N, Kuehl T, Ryan J, Bhola P, Montero J, Kapoor M, Baron M, Varelas X, Tschumperlin DJ, Letai A, Tager AM. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Sci Transl Med. 2017 Dec 13; 9(420). PMID: 29237758.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  21. Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, Konopleva M, Letai A. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. Cancer Discov. 2017 12; 7(12):1376-1393. PMID: 29146569.
    Citations: 4     Fields:    Translation:Humans
  22. Saito Y, Mochizuki Y, Ogahara I, Watanabe T, Hogdal L, Takagi S, Sato K, Kaneko A, Kajita H, Uchida N, Fukami T, Shultz LD, Taniguchi S, Ohara O, Letai AG, Ishikawa F. Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways. Sci Transl Med. 2017 Oct 25; 9(413). PMID: 29070697.
    Citations:    Fields:    Translation:HumansAnimalsCells
  23. Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP. BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nat Commun. 2017 10 24; 8(1):1123. PMID: 29066722.
    Citations:    
  24. Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, Yong WH, Kornblum HI, Bensinger SJ, Mischel PS, Rao PN, Clark PM, Cloughesy TF, Letai A, Nathanson DA. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nat Med. 2017 Nov; 23(11):1342-1351. PMID: 29035366.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  25. Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215. PMID: 28967922.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  26. Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med. 2017 Sep 08; 23(9):1028-1035. PMID: 28886003.
    Citations: 12     Fields:    Translation:HumansCells
  27. Jenson JM, Ryan JA, Grant RA, Letai A, Keating AE. Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. Elife. 2017 06 08; 6. PMID: 28594323.
    Citations: 2     Fields:    Translation:Cells
  28. Zwang Y, Jonas O, Chen C, Rinne ML, Doench JG, Piccioni F, Tan L, Huang HT, Wang J, Ham YJ, O'Connell J, Bhola P, Doshi M, Whitman M, Cima M, Letai A, Root DE, Langer RS, Gray N, Hahn WC. Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 2017 05 31; 6. PMID: 28561737.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  29. Price AM, Dai J, Bazot Q, Patel L, Nikitin PA, Djavadian R, Winter PS, Salinas CA, Barry AP, Wood KC, Johannsen EC, Letai A, Allday MJ, Luftig MA. Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection. Elife. 2017 04 20; 6. PMID: 28425914.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  30. Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, Davis SP, Lobera M, Nolan MA, Letai A. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 2017 03 16; 543(7645):428-432. PMID: 28273064.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  31. Pallis M, Burrows F, Ryan J, Grundy M, Seedhouse C, Abdul-Aziz A, Montero J, Letai A, Russell N. Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget. 2017 Mar 07; 8(10):16220-16232. PMID: 27092880.
    Citations: 3     Fields:    Translation:HumansCells
  32. Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017 10; 31(10):2075-2084. PMID: 28111464.
    Citations: 14     Fields:    Translation:HumansCells
  33. Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, Liao R, Walsh D, Sedivy J, Murphy DJ, Carrasco DR, Robinson S, Moslehi J, Letai A. Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. Cancer Cell. 2017 01 09; 31(1):142-156. PMID: 28017613.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  34. Pécot J, Maillet L, Le Pen J, Vuillier C, Trécesson SC, Fétiveau A, Sarosiek KA, Bock FJ, Braun F, Letai A, Tait SWG, Gautier F, Juin PP. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance. Cell Rep. 2016 12 20; 17(12):3347-3358. PMID: 28009301.
    Citations: 5     Fields:    Translation:HumansCells
  35. Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N, Matulis SM, Koss B, Fischer MA, Arnold AL, Camper DV, Browning CF, Rossanese OW, Budhraja A, Opferman J, Boise LH, Savona MR, Letai A, Olejniczak ET, Fesik SW. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS Lett. 2017 Jan; 591(1):240-251. PMID: 27878989.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  36. Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164. PMID: 27986708.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  37. Letai A. S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver. Cancer Cell. 2016 Dec 12; 30(6):834-835. PMID: 27960083.
    Citations: 2     Fields:    Translation:HumansAnimals
  38. Taylor-Weiner A, Zack T, O'Donnell E, Guerriero JL, Bernard B, Reddy A, Han GC, AlDubayan S, Amin-Mansour A, Schumacher SE, Litchfield K, Turnbull C, Gabriel S, Beroukhim R, Getz G, Carter SL, Hirsch MS, Letai A, Sweeney C, Van Allen EM. Genomic evolution and chemoresistance in germ-cell tumours. Nature. 2016 11 30; 540(7631):114-118. PMID: 27905446.
    Citations: 12     Fields:    Translation:HumansCells
  39. Potter DS, Letai A. To Prime, or Not to Prime: That Is the Question. Cold Spring Harb Symp Quant Biol. 2016; 81:131-140. PMID: 27811212.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  40. Pham TD, Pham PQ, Li J, Letai AG, Wallace DC, Burke PJ. Cristae remodeling causes acidification detected by integrated graphene sensor during mitochondrial outer membrane permeabilization. Sci Rep. 2016 10 27; 6:35907. PMID: 27786282.
    Citations: 1     Fields:    Translation:HumansCells
  41. Sarosiek KA, Letai A. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise. FEBS J. 2016 10; 283(19):3523-3533. PMID: 26996748.
    Citations: 12     Fields:    Translation:HumansCells
  42. Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016 11 15; 76(22):6495-6506. PMID: 27671678.
    Citations: 10     Fields:    Translation:HumansCells
  43. Bhola PD, Mar BG, Lindsley RC, Ryan JA, Hogdal LJ, Vo TT, DeAngelo DJ, Galinsky I, Ebert BL, Letai A. Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. J Clin Invest. 2016 10 03; 126(10):3827-3836. PMID: 27599292.
    Citations: 2     Fields:    Translation:HumansCells
  44. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016 10; 6(10):1106-1117. PMID: 27520294.
    Citations: 53     Fields:    Translation:HumansCTClinical Trials
  45. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. PMID: 27479034.
    Citations: 13     Fields:    
  46. Ryan J, Montero J, Rocco J, Letai A. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016 07 01; 397(7):671-8. PMID: 26910743.
    Citations: 11     Fields:    Translation:HumansCells
  47. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589. PMID: 27199251.
    Citations: 32     Fields:    Translation:Humans
  48. Brem EA, Letai A. BOK: Oddball of the BCL-2 Family. Trends Cell Biol. 2016 06; 26(6):389-390. PMID: 27156889.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  49. Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, Letai A, Roberts AW. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016 06 23; 127(25):3215-24. PMID: 27069256.
    Citations: 25     Fields:    Translation:HumansAnimalsCells
  50. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. PMID: 27070704.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  51. Montero J, Letai A. Dynamic BH3 profiling-poking cancer cells with a stick. Mol Cell Oncol. 2016 May; 3(3):e1040144. PMID: 27314085.
    Citations: 5     
  52. Koss B, Ryan J, Budhraja A, Szarama K, Yang X, Bathina M, Cardone MH, Nikolovska-Coleska Z, Letai A, Opferman JT. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines. Oncotarget. 2016 Mar 08; 7(10):11500-11. PMID: 26862853.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  53. Bhola PD, Letai A. Mitochondria-Judges and Executioners of Cell Death Sentences. Mol Cell. 2016 Mar 03; 61(5):695-704. PMID: 26942674.
    Citations: 33     Fields:    Translation:HumansAnimalsCells
  54. Rezaei Araghi R, Ryan JA, Letai A, Keating AE. Rapid Optimization of Mcl-1 Inhibitors using Stapled Peptide Libraries Including Non-Natural Side Chains. ACS Chem Biol. 2016 05 20; 11(5):1238-44. PMID: 26854535.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  55. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015 Dec 29; 13(12):2715-27. PMID: 26711339.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  56. Letai A. Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell! Clin Cancer Res. 2015 Nov 15; 21(22):5015-20. PMID: 26567360.
    Citations: 7     Fields:    Translation:Humans
  57. Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015 Dec; 15(12):747-56. PMID: 26536825.
    Citations: 69     Fields:    Translation:Humans
  58. Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, Klebanov B, Landesman Y, Kauffman M, Shacham S, Kung AL, Wang JC, Letai A, Look AT. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2016 Jan; 30(1):190-9. PMID: 26202935.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  59. Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood. 2015 Sep 24; 126(13):1555-64. PMID: 26194763.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  60. Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, Richardson P, Anderson K, Amiot M, Letai A. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016 Mar; 30(3):761-4. PMID: 26174630.
    Citations: 20     Fields:    Translation:HumansCells
  61. Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dölemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41. PMID: 26175414.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  62. Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015 Feb 26; 160(5):977-989. PMID: 25723171.
    Citations: 64     Fields:    Translation:HumansCells
  63. Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Sci Signal. 2014 Dec 23; 7(357):ra122. PMID: 25538080.
    Citations: 21     Fields:    Translation:HumansCells
  64. Dutta S, Ryan J, Chen TS, Kougentakis C, Letai A, Keating AE. Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL. J Mol Biol. 2015 Mar 27; 427(6 Pt B):1241-1253. PMID: 25451027.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  65. Bah N, Maillet L, Ryan J, Dubreil S, Gautier F, Letai A, Juin P, Barillé-Nion S. Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis. 2014; 5:e1429. PMID: 25275590.
    Citations:    
  66. Foight GW, Ryan JA, Gullá SV, Letai A, Keating AE. Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol. 2014 Sep 19; 9(9):1962-8. PMID: 25052212.
    Citations: 24     Fields:    Translation:HumansCells
  67. Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, Jones L, Manesh DM, Kurmasheva RT, Billups C, Kaplan W, Letai A, Bourquin JP, Houghton PJ, Smith MA, Lock RB. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2014 Sep 01; 20(17):4520-31. PMID: 25013123.
    Citations: 16     Fields:    Translation:Humans
  68. Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014 Sep; 4(9):1074-87. PMID: 24994123.
    Citations: 35     Fields:    Translation:HumansAnimalsCells
  69. Bah N, Maillet L, Ryan J, Dubreil S, Gautier F, Letai A, Juin P, Barillé-Nion S. Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis. 2014 Jun 12; 5:e1291. PMID: 24922075.
    Citations: 16     Fields:    Translation:HumansCells
  70. Wan L, Tan M, Yang J, Inuzuka H, Dai X, Wu T, Liu J, Shaik S, Chen G, Deng J, Malumbres M, Letai A, Kirschner MW, Sun Y, Wei W. APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Dev Cell. 2014 May 27; 29(4):377-91. PMID: 24871945.
    Citations: 27     Fields:    Translation:HumansCells
  71. Murase K, Kim HT, Bascug OR, Kawano Y, Ryan J, Matsuoka K, Davids MS, Koreth J, Ho VT, Cutler C, Armand P, Alyea EP, Blazar BR, Antin JH, Soiffer RJ, Letai A, Ritz J. Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508. PMID: 24859877.
    Citations: 6     Fields:    Translation:HumansCells
  72. Murphy ÁC, Weyhenmeyer B, Noonan J, Kilbride SM, Schimansky S, Loh KP, Kögel D, Letai AG, Prehn JH, Murphy BM. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis. Apoptosis. 2014 Apr; 19(4):629-42. PMID: 24213561.
    Citations: 18     Fields:    Translation:HumansCells
  73. Colak S, Zimberlin CD, Fessler E, Hogdal L, Prasetyanti PR, Grandela CM, Letai A, Medema JP. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ. 2014 Jul; 21(7):1170-7. PMID: 24682005.
    Citations: 25     Fields:    Translation:HumansCells
  74. Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res. 2014 Jun 01; 74(11):3146-56. PMID: 24675361.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  75. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75. PMID: 24346116.
    Citations: 99     Fields:    Translation:HumansAnimalsCells
  76. Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L, Flanagan A, Andrews DW, Sorger P, Letai A. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell. 2013 Sep 26; 51(6):751-65. PMID: 24074954.
    Citations: 65     Fields:    Translation:HumansCells
  77. Sarosiek KA, Ni Chonghaile T, Letai A. Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol. 2013 Dec; 23(12):612-9. PMID: 24060597.
    Citations: 36     Fields:    Translation:HumansAnimalsCells
  78. Liu JC, Guan X, Ryan JA, Rivera AG, Mock C, Agrawal V, Agarwal V, Letai A, Lerou PH, Lahav G. High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis. Cell Stem Cell. 2013 Oct 03; 13(4):483-91. PMID: 23954752.
    Citations: 46     Fields:    Translation:HumansCells
  79. Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013 Aug; 54(8):1823-5. PMID: 23614795.
    Citations: 11     Fields:    Translation:HumansCells
  80. Montero J, Dutta C, van Bodegom D, Weinstock D, Letai A. p53 regulates a non-apoptotic death induced by ROS. Cell Death Differ. 2013 Nov; 20(11):1465-74. PMID: 23703322.
    Citations: 42     Fields:    Translation:HumansCells
  81. Ryan J, Letai A. BH3 profiling in whole cells by fluorimeter or FACS. Methods. 2013 Jun 01; 61(2):156-64. PMID: 23607990.
    Citations: 43     Fields:    Translation:HumansCells
  82. Hogdal LJ, Letai A. BCL-2 inhibition: stemming the tide of myeloid malignancies. Cell Stem Cell. 2013 Mar 07; 12(3):269-70. PMID: 23472867.
    Citations: 2     Fields:    Translation:HumansCells
  83. Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013 Feb 11; 23(2):139-41. PMID: 23410971.
    Citations: 33     Fields:    
  84. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013 Apr; 161(1):117-27. PMID: 23373539.
    Citations: 65     Fields:    Translation:HumansAnimalsCells
  85. Deng J, Letai A. Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer. Breast Cancer Res. 2013; 15(5):317. PMID: 24172207.
    Citations: 2     Fields:    Translation:HumansAnimals
  86. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012 Oct 12; 151(2):344-55. PMID: 23063124.
    Citations: 99     Fields:    Translation:HumansCells
  87. Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012 Oct; 2(10):934-47. PMID: 22961667.
    Citations: 83     Fields:    Translation:HumansAnimalsCells
  88. Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012 Oct 25; 120(17):3501-9. PMID: 22955911.
    Citations: 43     Fields:    Translation:HumansCells
  89. Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM. BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 2012 Aug 15; 72(16):4193-203. PMID: 22689920.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  90. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 2012 Sep 01; 30(25):3127-35. PMID: 22649144.
    Citations: 76     Fields:    Translation:HumansAnimals
  91. Rodriguez DA, Zamorano S, Lisbona F, Rojas-Rivera D, Urra H, Cubillos-Ruiz JR, Armisen R, Henriquez DR, Cheng EH, Letek M, Vaisar T, Irrazabal T, Gonzalez-Billault C, Letai A, Pimentel-Muiños FX, Kroemer G, Hetz C. BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1a. EMBO J. 2012 May 16; 31(10):2322-35. PMID: 22510886.
    Citations: 33     Fields:    Translation:AnimalsCells
  92. Del Gaizo Moore V, Letai A. BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013 May 28; 332(2):202-5. PMID: 22230093.
    Citations: 38     Fields:    Translation:HumansCells
  93. Ni Chonghaile T, Letai A. Who put the "A" in Atg12: autophagy or apoptosis? Mol Cell. 2011 Dec 23; 44(6):844-5. PMID: 22195958.
    Citations: 5     Fields:    
  94. Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, Patton JT, Maiso P, Monrose V, Sacco A, Ngo HT, Flores LM, Lin CP, Magnani JL, Kung AL, Letai A, Carrasco R, Roccaro AM, Ghobrial IM. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012 Feb 09; 119(6):1468-78. PMID: 22096244.
    Citations: 31     Fields:    Translation:HumansAnimalsCells
  95. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33. PMID: 22033517.
    Citations: 188     Fields:    Translation:HumansAnimalsCells
  96. Letai A. Targeting Bcl-2 in CLL: cui bono? Blood. 2011 Sep 29; 118(13):3453-4. PMID: 21960677.
    Citations:    Fields:    
  97. Barbone D, Ryan JA, Kolhatkar N, Chacko AD, Jablons DM, Sugarbaker DJ, Bueno R, Letai AG, Coussens LM, Fennell DA, Broaddus VC. The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Cell Death Dis. 2011 Jun 23; 2:e174. PMID: 21697949.
    Citations: 16     Fields:    Translation:HumansCells
  98. Letai A. A new face of BCL-2 inhibition in CLL. Blood. 2011 Mar 10; 117(10):2750-1. PMID: 21393499.
    Citations: 1     Fields:    
  99. Ryan JA, Brunelle JK, Letai A. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci U S A. 2010 Jul 20; 107(29):12895-900. PMID: 20615979.
    Citations: 57     Fields:    Translation:HumansAnimalsCells
  100. Kutuk O, Letai A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ. 2010 Oct; 17(10):1624-35. PMID: 20431602.
    Citations: 30     Fields:    Translation:HumansCells
  101. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010 Apr 22; 115(16):3304-13. PMID: 20197552.
    Citations: 136     Fields:    Translation:HumansCells
  102. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905. PMID: 20164920.
    Citations: 1134     Fields:    Translation:HumansCells
  103. Vo TT, Letai A. BH3-only proteins and their effects on cancer. Adv Exp Med Biol. 2010; 687:49-63. PMID: 20919637.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  104. Brunelle JK, Ryan J, Yecies D, Opferman JT, Letai A. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J Cell Biol. 2009 Nov 02; 187(3):429-42. PMID: 19948485.
    Citations: 37     Fields:    Translation:Animals
  105. Berger AK, Cortese GP, Amodeo KD, Weihofen A, Letai A, LaVoie MJ. Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Hum Mol Genet. 2009 Nov 15; 18(22):4317-28. PMID: 19679562.
    Citations: 36     Fields:    Translation:HumansAnimalsCells
  106. Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, Takada K, Carlson NE, Carrasco DE, Tai YT, Raje N, Letai AG, Anderson KC, Carrasco DR. Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood. 2009 Sep 24; 114(13):2699-708. PMID: 19652203.
    Citations: 34     Fields:    Translation:HumansAnimalsCells
  107. Letai A. Hiding from ABT-737 in lymph nodes. Blood. 2009 Apr 30; 113(18):4132-3. PMID: 19406997.
    Citations: 1     Fields:    
  108. Letai A. Puma strikes Bax. J Cell Biol. 2009 Apr 20; 185(2):189-91. PMID: 19380876.
    Citations: 11     Fields:    Translation:HumansCells
  109. Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 2009 Feb 15; 122(Pt 4):437-41. PMID: 19193868.
    Citations: 230     Fields:    Translation:HumansAnimalsCells
  110. Ni Chonghaile T, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene. 2008 Dec; 27 Suppl 1:S149-57. PMID: 19641500.
    Citations: 92     Fields:    Translation:HumansAnimalsCells
  111. Kutuk O, Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 2008 Oct 01; 68(19):7985-94. PMID: 18829556.
    Citations: 46     Fields:    Translation:HumansCells
  112. Jette CA, Flanagan AM, Ryan J, Pyati UJ, Carbonneau S, Stewart RA, Langenau DM, Look AT, Letai A. BIM and other BCL-2 family proteins exhibit cross-species conservation of function between zebrafish and mammals. Cell Death Differ. 2008 Jun; 15(6):1063-72. PMID: 18404156.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  113. Kutuk O, Letai A. Regulation of Bcl-2 family proteins by posttranslational modifications. Curr Mol Med. 2008 Mar; 8(2):102-18. PMID: 18336291.
    Citations: 36     Fields:    Translation:HumansAnimalsCells
  114. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer. 2008 Feb; 8(2):121-32. PMID: 18202696.
    Citations: 207     Fields:    Translation:HumansAnimalsCells
  115. Del Gaizo Moore V, Letai A. Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? Adv Exp Med Biol. 2008; 615:159-75. PMID: 18437895.
    Citations: 10     Fields:    Translation:HumansAnimals
  116. Anthony Letai and Victoria Del Gaizo Moore. Apoptosis Dysregulation in CLL. Chronic Lymphocytic Leukemia. 2008.
  117. Del Gaizo Moore VD, Letai A. Rational design of therapeutics targeting the BCL-2 famil: Are some cancer cells primed for death but waiting for a final push?. Programmed Cell Death in Cancer Progression and Therapy. 2008; 159-176.
  118. Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res. 2007 Dec 15; 67(24):11867-75. PMID: 18089817.
    Citations: 68     Fields:    Translation:HumansCells
  119. Flanagan AM, Letai A. BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2. Cell Death Differ. 2008 Mar; 15(3):580-8. PMID: 18084238.
    Citations: 29     Fields:    Translation:HumansCells
  120. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008 Feb 15; 111(4):2300-9. PMID: 18056841.
    Citations: 63     Fields:    Translation:HumansCells
  121. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007 Aug; 12(2):171-85. PMID: 17692808.
    Citations: 187     Fields:    Translation:HumansCells
  122. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007 Jan; 117(1):112-21. PMID: 17200714.
    Citations: 205     Fields:    Translation:HumansCells
  123. Letai A. Restoring cancer's death sentence. Cancer Cell. 2006 Nov; 10(5):343-5. PMID: 17097553.
    Citations: 11     Fields:    Translation:HumansAnimals
  124. Letai A, Scorrano L. Laying the foundations of programmed cell death. Cell Death Differ. 2006 Aug; 13(8):1245-7. PMID: 16838033.
    Citations: 1     Fields:    Translation:AnimalsCells
  125. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006 May; 9(5):351-65. PMID: 16697956.
    Citations: 402     Fields:    Translation:AnimalsCells
  126. Goldsmith KC, Liu X, Dam V, Morgan BT, Shabbout M, Cnaan A, Letai A, Korsmeyer SJ, Hogarty MD. BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene. 2006 Aug 03; 25(33):4525-33. PMID: 16568093.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  127. Letai A. Growth factor withdrawal and apoptosis: the middle game. Mol Cell. 2006 Mar 17; 21(6):728-30. PMID: 16543140.
    Citations: 13     Fields:    Translation:Cells
  128. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005 Nov; 8(5):407-19. PMID: 16286248.
    Citations: 168     Fields:    Translation:HumansAnimalsCells
  129. Letai A. BCL-2: found bound and drugged! Trends Mol Med. 2005 Oct; 11(10):442-4. PMID: 16150641.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  130. Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest. 2005 Oct; 115(10):2648-55. PMID: 16200198.
    Citations: 35     Fields:    Translation:HumansAnimalsCells
  131. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005 Jun 02; 435(7042):677-81. PMID: 15902208.
    Citations: 1031     Fields:    Translation:HumansAnimalsCells
  132. Anthony G. Letai John G. Gribben. Lymphoid Neoplasms. Molecular Hematology. 2005; 105-114.
  133. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell. 2004 Sep; 6(3):241-9. PMID: 15380515.
    Citations: 61     Fields:    Translation:HumansAnimalsCells
  134. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003 Dec 11; 426(6967):671-6. PMID: 14668867.
    Citations: 276     Fields:    Translation:AnimalsCells
  135. Letai AG. Smallpox and smallpox vaccination. N Engl J Med. 2003 May 08; 348(19):1920-5; author reply 1920-5. PMID: 12736287.
    Citations:    Fields:    Translation:HumansPHPublic Health
  136. Letai A. BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics. Expert Opin Biol Ther. 2003 Apr; 3(2):293-304. PMID: 12662143.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  137. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002 Sep; 2(3):183-92. PMID: 12242151.
    Citations: 482     Fields:    Translation:HumansAnimalsCells
  138. Letai A, Kuter DJ. Cancer, coagulation, and anticoagulation. Oncologist. 1999; 4(6):443-9. PMID: 10631688.
    Citations: 9     Fields:    Translation:Humans
  139. Letai A, Fuchs E. The importance of intramolecular ion pairing in intermediate filaments. Proc Natl Acad Sci U S A. 1995 Jan 03; 92(1):92-6. PMID: 7816855.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  140. Fuchs E, Coulombe P, Cheng J, Chan YM, Hutton E, Syder A, Degenstein L, Yu QC, Letai A, Vassar R. Genetic bases of epidermolysis bullosa simplex and epidermolytic hyperkeratosis. J Invest Dermatol. 1994 Nov; 103(5 Suppl):25S-30S. PMID: 7525738.
    Citations: 10     Fields:    Translation:HumansCells
  141. Letai A, Coulombe PA, McCormick MB, Yu QC, Hutton E, Fuchs E. Disease severity correlates with position of keratin point mutations in patients with epidermolysis bullosa simplex. Proc Natl Acad Sci U S A. 1993 Apr 15; 90(8):3197-201. PMID: 7682695.
    Citations: 33     Fields:    Translation:HumansCells
  142. Anthony Letai. Keratin Mutations and Heritable Skin Disease. 1993.
  143. Cheng J, Syder AJ, Yu QC, Letai A, Paller AS, Fuchs E. The genetic basis of epidermolytic hyperkeratosis: a disorder of differentiation-specific epidermal keratin genes. Cell. 1992 Sep 04; 70(5):811-9. PMID: 1381287.
    Citations: 53     Fields:    Translation:HumansCells
  144. Letai A, Coulombe PA, Fuchs E. Do the ends justify the mean? Proline mutations at the ends of the keratin coiled-coil rod segment are more disruptive than internal mutations. J Cell Biol. 1992 Mar; 116(5):1181-95. PMID: 1371287.
    Citations: 22     Fields:    Translation:HumansCells
  145. Coulombe PA, Hutton ME, Letai A, Hebert A, Paller AS, Fuchs E. Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: genetic and functional analyses. Cell. 1991 Sep 20; 66(6):1301-11. PMID: 1717157.
    Citations: 129     Fields:    Translation:HumansCells
  146. Lloyd DM, Cotler SJ, Letai AG, Stuart FP, Thistlethwaite JR. Pancreas-graft immunogenicity and pretreatment with anti-class II monoclonal antibodies. Diabetes. 1989 Jan; 38 Suppl 1:104-8. PMID: 2642828.
    Citations:    Fields:    Translation:Animals
  147. Letai AG, Palladino MA, Fromm E, Rizzo V, Fresco JR. Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide affinity columns. Biochemistry. 1988 Dec 27; 27(26):9108-12. PMID: 3242616.
    Citations: 39     Fields:    Translation:Cells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Letai's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (476)
Explore
_
Co-Authors (192)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.